There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no longer in shortage after nearly two years. Pharmacies that sold unbranded copies of those drugs are mounting a coordinated effort to reverse this decision,

The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide from its shortage list.

FDA halts actions on makers of compounded drugs as it reviews decision to remove Eli Lilly's (LLY) weight loss drug tirzepatide from its shortage list. Read more here.